CPG
TMBR

Cornerstone Planning Group’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Cornerstone Planning Group’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-159
Closed -$386 – 1318
2023
Q2 		$386 Buy
+159
New +$262 ﹤0.01% 1479
2022
Q4 		$312 Buy
+159
New +$386 ﹤0.01% 1491

Other funds holding TMBR

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cornerstone Planning Group's TMBR Position: Q3 2023 in Review

Cornerstone Planning Group sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2023, closing a stake of 159 shares — an estimated $386 sold.

Cornerstone Planning Group first reported a position in TMBR in Q4 2022 and held it in 2 quarters. The position peaked at $386 in Q2 2023. 11 funds tracked by Wall St. Rank hold TMBR as of Q3 2023.

  • Cornerstone Planning Group reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Cornerstone Planning Group sold 159 Timber Pharmaceuticals, Inc. shares in Q3 2023, an estimated $386.
  • Cornerstone Planning Group first reported a position in Timber Pharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
  • Cornerstone Planning Group's Timber Pharmaceuticals, Inc. position peaked at $386 in Q2 2023.
  • 11 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2023.

Based on Cornerstone Planning Group's 13F filing for Q3 2023, filed 8 Nov 2023.